The potential use of SLC6A19 as a target to improve metabolic disease is further exemplified by the ability of SLC6A19ko to normalize the elevated levels of phenylalanine in a mouse model of phenylketonuria [32]. Here, SLC6A19 is linked to metabolic disease.